Terry Hermiston
Founder at Coagulant Therapeutics, Inc.
Profile
Terry Hermiston is the founder of Coagulant Therapeutics, Inc. which was founded in 2019, where he holds the title of Chief Executive Officer & Director.
He currently holds positions as a Director at Kalivir Immunotherapeutics, Inc. and as Vice President-Biologics Research at Bayer HealthCare Pharmaceuticals, Inc. Dr. Hermiston previously held the position of Director at SillaJen Biotherapeutics, Inc. and Director at California Healthcare Institute.
Terry Hermiston active positions
Companies | Position | Start |
---|---|---|
Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Bayer HealthCare Pharmaceuticals, Inc. manufactures pharmaceutical drugs. It offers pharmaceuticals and therapeutics in the areas of diagnostic imaging, hematology and cardiology, cancer, women's health and several other chronic diseases such as multiple sclerosis and Parkinson's disease. Bayer HealthCare Pharmaceuticals was founded in 1979 and is located in Wayne, NJ. | Corporate Officer/Principal | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | Director/Board Member | - |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Founder | 2018-12-31 |
Former positions of Terry Hermiston
Companies | Position | End |
---|---|---|
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Director/Board Member | - |
California Healthcare Institute | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 5 |
---|---|
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
California Healthcare Institute | Health Technology |
Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Bayer HealthCare Pharmaceuticals, Inc. manufactures pharmaceutical drugs. It offers pharmaceuticals and therapeutics in the areas of diagnostic imaging, hematology and cardiology, cancer, women's health and several other chronic diseases such as multiple sclerosis and Parkinson's disease. Bayer HealthCare Pharmaceuticals was founded in 1979 and is located in Wayne, NJ. | Health Technology |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | Health Technology |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Health Technology |
- Stock Market
- Insiders
- Terry Hermiston